Evidence map›Paper›PMID 40707954›Full record

ArticleJournal of translational medicine2025

A multi-omic single-cell landscape reveals transcription and epigenetic regulatory features of t(8;21) AML.

Xue-Ping Li, Yan Gao, Bai-Tian Zhao, Yu-Ting Dai, Jia-Ying Mao, Yang Liang, Lu Jiang

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xue-Ping Li *Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.ORCID 0000-0002-4588-065X
Yan Gao *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Bai-Tian ZhaoState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Yu-Ting DaiShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jia-Ying MaoState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Yang LiangDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. liangyang@sysucc.org.cn.
Lu JiangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. jl11891@rjh.com.cn.

Funding

Fundamental Research Funds for the Central Universities 24qnpy291National Natural Science Foundation of China 82270170National Natural Science Foundation of China 82300184Shanghai Rising-Star Program 22QA1405600
6 · The paper itself

Abstract

backgroundComprehensive analysis of single-cell transcriptome and chromatin accessibility will contribute to interpret the heterogeneity of acute myeloid leukemia (AML). We hypothesize that integrating single-cell transcriptomic and chromatin accessibility landscapes underlying t(8;21) AML will provide valuable insights into its heterogeneous cellular properties and gene regulatory programs.

methodsHere, we conducted paired single-cell RNA-sequencing (scRNA-seq) and single-cell ATAC sequencing on bone marrow samples from newly diagnosed t(8;21) AML patients and healthy controls. Genetic signatures extracted from scRNA-seq were built and validated across three independent cohorts (German AMLCG1999, GSE106291 and TCGA LAML).

resultsWe identified TCF12, a core component of AML1-ETO-containing transcription factor complex (AETFC), as the most active transcription factor in blast cells, driving a universally repressed chromatin state. Furthermore, we delineated two functionally distinct T cell subsets, revealing that EOMES-mediated transcriptional regulation promotes the expansion of a cytotoxic T cell population (T cells_2; high GNLY, NKG7 and GZMB expression), with an increased clonality and a tendency for drug resistance. In addition, we discovered a novel leukemic CMP-like cluster characterized by high TPSAB1, HPGD and FCER1A expression. Leveraging machine learning-based integration of multi-omic profiles, we identified a robust 9-gene prognostic signature, which demonstrated significant predictive value for AML outcomes across three independent cohorts.

conclusionsThis multi-omics study provides unprecedented insights into the transcriptional and epigenetic heterogeneity of t(8;21) AML, providing a potential actionable tool for clinical risk stratification.

Indexed as

Chromosomes, Human, Pair 21Chromosomes, Human, Pair 8Epigenesis, GeneticLeukemia, Myeloid, AcuteSingle-Cell AnalysisTranscription, GeneticTranslocation, GeneticAdultChromatinFemaleGene Expression Regulation, LeukemicHumansMaleMiddle AgedMultiomicsReproducibility of ResultsChromatinscATAC-seqscRNA-seqT(8;21) AMLTCR repertoire

Identifiers

PMID40707954
PMCPMC12288317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.